The UK government has issued several documents to help businesses in planning for the eventuality of a no-deal Brexit, but the UK’s Brexit Health Alliance says “the guidance is a first step
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh